Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.2K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.8K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.5K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reproductive health in Ireland: moving forward as others roll back.

The Lancet. Haematology·2026
Same author

CX3CR1<sup>+</sup> synovial macrophages accumulate in the joint during experimental hemophilic arthropathy but are not required for acute synovitis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Monovalent antibody treatment of von Willebrand disease.

Blood advances·2026
Same author

Contrary to current guidance, antenatal factor IX levels increase in female carriers of hemophilia B.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Nine areas with outstanding challenges for hemophilia B research.

Therapeutic advances in hematology·2026
Same author

The IL-33 receptor ST2 as a therapeutic target for hemophilic arthropathy.

Expert opinion on therapeutic targets·2026

Related Experiment Video

Updated: Dec 21, 2025

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.6K

New developments in von Willebrand disease.

Helen Fogarty1,2, Dearbhla Doherty1, James S O'Donnell1,2,3

  • 1Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.

British Journal of Haematology
|May 13, 2020
PubMed
Summary

Von Willebrand disease (VWD) is a common inherited bleeding disorder. Recent advances in laboratory assays and understanding of von Willebrand factor (VWF) are improving VWD diagnosis and treatment.

Keywords:
Low VWFvon Willebrand diseasevon Willebrand factor

More Related Videos

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.0K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K

Related Experiment Videos

Last Updated: Dec 21, 2025

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

11.6K
Live-cell Imaging of Platelet Degranulation and Secretion Under Flow
11:42

Live-cell Imaging of Platelet Degranulation and Secretion Under Flow

Published on: July 10, 2017

12.0K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.3K

Area of Science:

  • Hematology
  • Genetics
  • Clinical Medicine

Background:

  • Von Willebrand disease (VWD) is the most frequent inherited bleeding disorder, characterized by mucocutaneous bleeding.
  • VWD diagnosis and subclassification present clinical challenges due to wide variations in normal plasma von Willebrand factor (VWF) levels and VWF's complex functions.
  • Despite its prevalence, VWD diagnosis remains complex, impacting patient quality of life.

Purpose of the Study:

  • To review recent advancements in understanding the biological roles and pathophysiological mechanisms of VWF in VWD.
  • To discuss new laboratory assays for precise VWF activity assessment.
  • To explore the impact of these advances on clinical diagnostic algorithms and VWD management strategies.

Main Methods:

  • Review of recent scientific literature on VWD, VWF biology, and diagnostic methodologies.
  • Analysis of newly developed laboratory assays for VWF assessment.
  • Evaluation of current and emerging treatment options for VWD.

Main Results:

  • Substantial progress in elucidating VWF's biological roles and the pathophysiology of VWD.
  • Development of novel laboratory assays enabling more accurate assessment of VWF function.
  • Identification of improved diagnostic approaches and treatment strategies for VWD.

Conclusions:

  • Recent advances in VWF research and assay development are significantly improving VWD diagnosis and subclassification.
  • These developments offer potential for enhanced clinical diagnostic algorithms and more effective patient management.
  • Continued research into VWD pathophysiology and treatment is crucial for improving patient outcomes.